FIFTEEN YEARS HAVE PASSED SINCE human CD38 (then referred to as T1O antigen) was first identified by means of monoclonal antibodies (mAbs)2 directed against human T lymphocytes (1). Using these antibodies, the CD38 antigen was found to have a rather unique distribution pattern, being predominantly expressed by progenitors and early hematopoietic cells, then lost during maturation, only to be reexpressed during cell activation. Because of this curious pattern of expression, CD38 has been used primarily as a phenotypic marker of differentiation in normal and leukemic blood cells. However, interest in CD38 antigen beyond its use as a marker of cellular differentiation has grown recently after a report that human CD38 has significant amino acid sequence similarity to ADP-ribosyl cyclase (2), a 29 kDA cytosolic enzyme previously isolated from a sea mollusc, Aplysia caljfornica (3, 4) .
Aplysia
cyclase catalyzes the synthesis of cyclic ADPribose (cADPR) from NAD.
cADPR is a recently identified cyclic nucleotide with potent Ca2 mobilizing activity and has been proposed as an endogenous regulator of calcium-dependent calcium release (4, 5) . As predicted by its homology with Aplysia cyclase, human CD38 was recently
shown to act as a bifunctional ectoenzyme that catalyzes the conversion of NAD to cADPR and its further hydrolysis to ADP-ribose (ADPR) (6, 7) . Equally intriguing was the observation that agonistic mAbs against CD38 could trigger such diverse responses as growth, apoptosis, and protein phosphorylation in CD38 cells (8) , suggesting that CD38 could serve as an orphan receptor for an as yet unknown ligand.
Because mouse CD38 protein has been the subject of a recent review (9), we will restrict this review to human CD38. On the basis of information available, the clinical prospects of this molecule will be duscussed.
STRUCTURE OF CD38 AND RELATED MOLECULES
Human CD38 is a 45 kDa single-chain transmembrane glycoproteinwith a shortamino-terminal cytoplasmic tail, a single membrane-spanning region, and a long extracellular carboxy-terminal domain (Fig. 1) . The cDNAs encoding human, mouse, and rat CD38 have been cloned (10) (11) (12) , and the deduced amino acid sequences show significant homology among these CD38 pmteins ( Table  1) . 300 41 25 Activation Catalytic (23) . In the mouse, CD38 is expressed predominantly by B lymphocytes, both normal and transformed (9) . T lymphocytes and myeloid cells express variable amounts of surface CD38, but the expression is never as high as in the human counterparts.
The discrepancy between human and mouse CD38 expression could be explained by assuming that the murine CD38 belongs to the CD38 family but is not the exact analog of the human antigen.
The information available on rat CD38 is very limited and does not permit direct comparison with the human or mouse molecules.
The mRNA for CD38 in rats has been detected in the spleen, liver, heart, thymus, thyroid gland, adrenal gland, jejunum, and pancreatic islets (12) . The CD38-related molecule BST-1IBP-3 appears to be a surface molecule that is not restricted to any definite cell lineage (Table 2) .
ENZYMATIC FUNCTIONS
The enzymatic nature of CD38 has emerged recentlyafter the observation that ADP-ribosyl cyclase shares considerable structural homology with mouse and human CD38 (2). ADP-ribosyl cyclase catabolizes NAD to cADPR, a naturally occurring metabolite of NAD+ that serves as a second messenger for Ca2+ mobilization from intracellular sites (5) . A striking common feature of CD38 and ADP-ribosyl cyclase is that all 10 cysteine residues of the two proteins are perfectly conserved (2) , suggesting that these proteins may have similar secondary and tertiary structures and that CD38 may possess ADP-ribosyl cyclase activity. This possibility was testedby using the purified extracellular domain of recombinant CD38 protein, which indeed proved capable of converting NAD to cADPR (6) . Another intriguing observation was that purified CD38, in addition to ADP-ribosyl cyclase activity, also exhibited the abilityto hydrolyse cADPR to ADPR (6). These observations were subsequently confirmed and extended in several laboratories, and the results obtained established that CD38 proteins from human as well as mouse possess both cyclase and hydrolase activities (7, 12, 24, 25 to residues 119 and 201 of human CD38, enabled this protein to exhibit both the cyclase and the hydrolase activities (25) . The cysteme residues appear to be essential for maintaining the monomeric, catalytically active structure of CD38 without directly participating in its catalytic functions (26) . The overall reaction thus catalyzed by CD38 is the conversion of NAD to ADPR and nicotinamide, a reaction identical to that catalyzed by NAD-glycohydrolase (NADase). Though both these enzymes use NAD+ as a substrate, the products formed are different. The difficulties in detecting the formationof cADPR during CD38-catalyzed reactions have led to the frequent identification of CD38 as a classical NADase. A novelapproach was recentlydescribedtodistinguish CD38-like bifunctional enzymes from NADase. The use ofan alternative nucleotide, nicotinamideguanine dinucleotide (NGD), can preferentially reveal the cyclase activity of CD38 (27, 28) . The selective cyclase activity observed by using NGD as a substrateisdue tothefactthatthecyclic intermediate formed (cGDPR) is resistant to hydrolysis and thus preferentially accumulates during the reaction. However, unlike cADPR, cGPPR is inactive in mobilizing Ca2" from intracellular stores. In addition to NAD and NGD, human CD38 and Aplysia cyclasecan alsoutilize NADP as a substrate, leading to the synthesis of nicotinic acid adenine dinucleotide phosphate (NAADP). NAADP is another Ca2" mobilizing agent that acts on calcium stores that are different from those sensitive to inositol triphosphate and cADPR (29) . (24) . Human CD38 undergoes stable oligomerization in the presence of NAD or betamercaptoethanol, and this aggregation of CD38 is accompanied by a decrease in its ADP-ribosyl cyclase and NADase activities (36) . Self-aggregationof CD38 may thus represent a mechanism designed to down-regulate cADPR-dependent events. Furthermore, the catalytic functionsof human CD38 could also be alteredas a result of other posttranslational modifications. For example, in human myeloid leukemic cells (HL-60), RA treatment induces a rapid accumulation of CD38 (37) (38) (39) . After its synthesis,CD38 undergoes posttranslational modification into a high molecular mass form (190 kDa). This form of CD38 exhibits altered cyclase (fourfold higher) to hydrolase (threefold less)activities as compared to the 45 kDa native form (17) . Such a modification of CD38 may represent an important in vivo mechanism for regulating the catalytic functionsof thisbifunctional enzyme. 
REGULATION OF CELL-CELL INTERACTION
MEHTA El AL CD38 expression by RA. In general, mature circulating myeloid cells do not express CD38, nor could it be induced with RA. However, immature myeloid cells in the bone marrowexpression of CD38 can be reduced under certain conditions. For example, cells maintained at high density in culture or during activationundergo down-regulation of cell-
THANSMEMBHANE SIGNAUNG
The hypothesis that CD38 is involved in transmembrane signaling is based on a substantial body of data obtained in diverse experimental systems. For the sake of simplicity, the results will be grouped according to the cell lineage in which the signaling effects have been observed.
However, the results obtained in different cell lineages are too inconsistent to draw any definite conclusion. Most of the experiments involve the use of agonistic anti-CD38 mAbs, which should mimic the interactionbetween the CD38 receptor and its ligand (or ligands).
Effect on T cells
The first hint that CD38 might play a role in signaling came from the observations that ligation of CD38 on peripheral blood mononuclear cells and T cell lines induced activation and proliferation signals (8) . Subsequent experiments revealed that ligation of human CD38 with specific mAbs induces the transcription of cytokines interleukin-i (IL-i), tumor necrosis factor-alpha, and granulocyte-macrophage colony-stimulating factor at levels similar to those obtained after triggering T cell receptor CD3. However, the cytokines triggered in response to CD38 are qualitatively distinct from those induced via CD3 (46). For example, IL-6 mRNA and protein expression induced in response to CD38 ligation is greaterthan that induced via T cell receptor CD3. In contrast, interferon-gamma, IL-2, and IL-b transcription is higher aften activation by CD3 than after that by CD38. Another apparent difference in these two pathways is that CD38-mediated cytokine induction did not require either T cell proliferation or addition of antigen-presenting cells. The observation that signaling via CD38 in a T cell acute lymphoblastic leukemia (Jurkat) cell line led to Ca2 mobilization with kinetics that were distinct from those induced via T cell receptor CD3 lend further support to thisview (45 duced tyrosine phosphorylation of the protein kinase syk and resulted in an increase in its kinase activity. Phospholipase C-y and the p83 subunit of phosphatidyl-inositol-3-kinase (P1-3K) were also tyrosine phosphorylated after CD38 ligation (48) . In contrast to the signaling triggered by surface immunoglobulin (Ig) engagement in B lymphocytes, CD38 ligation did not induce tyrosinephosphorylation of the src-like protein tyrosine kinases lyn, fyn, and btk, or vav and ras GTPase-activating proteins. CD38 signaling also differed from cytokine-induced signaling in that it did not cause tyrosine phosphorylation of jaki and jak2. Finally, CD38 ligation did not inhibit IL-3-induced tyrosine phosphorylation of jak2 (48) .
Effects on myeloid cells
The only published report on CD38 signaling in myeloid cells used RA-induced human myeloid leukemia (HL-60) cells (49) . Retinoic acid rapidly induced an increase in expression of CD38 in these cells (37) (38) (39) . CD38 ligation in RA-differentiated HL-60 cells was followed by tyrosine phosphorylation of three major proteins: i20 kDa, 87 kDa, and 77 kDa. One of the major proteins tyrosine phosphorylated by CD38 ligation was identified as the ccbl proto-oncogene product pi200I. These results indicate that tyrosine phosphorylation of cellular proteins, including pi20c, may be an obligatory step in transmembrane signaling mediated by CD38.
CD38 IN DIAGNOSIS
AND THERAPY OF HUMAN DISEASES As discussed earlier, as a surface antigen useful for defining activation and proliferation states of normal and leukemic blood cells (i). The emergence of CD38 from this limited context required the accumulation of a formidable body of data over the course of many years. Consequently, CD38 passed from being a simple activation marker to a multifunctional surface receptor, possessing both complex enzymatic and cell-surface adhesion functions.
Despite this, the current association of CD38 in diverse human pathologies still reflects the notion that CD38 is an activation molecule (e.g., its expression in HIV-1-infected T cells) or a differentiation antigen (e.g., chronic B lymphocytic leukemia and myeloma).
Other reports stem from recent findings concerning its distribution (e.g., Alzheimer's disease) or from its newly attributed functions (e.g., Bruton's X-linked agammaglobulinemia). An alternative approach involving bispecific antibodies for delivery of other toxins in human acute T cell lymphoblasticleukemia uses CD7 and CD38 as targetmolecules (67);CD22 and CD38 in lymphoma have also been used (68) .A similarapproach was testedfortreatmentof B cell lymphoma using anti-CD19 and anti-CD38-saporin immunotoxin (69) . The results obtained from these studies suggest that anti-CD38-toxin immunoconjugates may be useful weapons in the treatment of myeloma, lymphoma, and leukemia.
In each case, the toxic potential on CD38-bearing tumor cellswas high, whereas effectson normal peripheral blood cells or hemopoietic progenitor cellswere negligible.
One potential limitation to the success of such a targeted approach to therapy is the heterogeneity of target antigen expression within a population of tumor cells. If a small number of cellswithin a tumor were negative for CD38 or expressed the antigen only very weakly, then these cells would escape destruction because the antibody-mediated delivery of the cytotoxic agent would fail to reach those particular cells. A possible means of overcoming this problem is to use agents that induce high levelsof CD38 on targetcells,in expectationthat tumor cellsthatwere antigen negative would express these target molecules in abundance. As discussed earlier, RA is one agent that induces high levels of CD38 expression in several leukemic cells and cell lines (37) (38) (39) (40) . In view of this, RA-induced CD38 could serve as useful target for optimal depletion of certain tumor cells while sparing normal cells.
CONCLUSION
In the past, CD38 has been viewed predominantly as a phenotypic marker of different subpopulations of T and B lymphocytes.
Recent findings on its roles as multifunc-tionalectoenzyme and as a modulator of signaltransduction pathways have renewed interestin this molecule. we regret that the work of several investigators who contributed to the subject could not be cited. We thank all the colleagues and investigators for useful suggestions and for making the unpublished data available for discussion. We also wish to thank Ms. Katherine Hale for editorial assistance.
